Leerink Partnrs Estimates IQVIA’s FY2024 Earnings (NYSE:IQV)

IQVIA Holdings Inc. (NYSE:IQV) – Investment analysts at Leerink Partnrs raised their FY2024 earnings estimates for shares of IQVIA in a report released on Tuesday, December 10th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $10.13 per share for the year, up from their prior forecast of $10.07. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2026 earnings at $12.26 EPS and FY2027 earnings at $13.70 EPS.

Other equities analysts also recently issued research reports about the stock. Truist Financial decreased their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday. Redburn Atlantic started coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Robert W. Baird reduced their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday. Bank of America decreased their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday. Finally, The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $256.19.

IQVIA Stock Down 0.7 %

Shares of IQVIA stock opened at $199.06 on Friday. The company’s fifty day simple moving average is $212.24 and its two-hundred day simple moving average is $224.21. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $36.13 billion, a P/E ratio of 26.12, a PEG ratio of 2.07 and a beta of 1.49.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IQV. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new position in IQVIA in the third quarter worth $28,000. Itau Unibanco Holding S.A. acquired a new position in IQVIA during the 2nd quarter valued at about $29,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the second quarter valued at about $32,000. Finally, Avior Wealth Management LLC increased its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.